This project aims to develop a novel class of drugs with the potential to overcome the stability problems previously associated with protein-based drugs. We will develop novel molecules for the treatment of cancer and cardiovascular disease. This project has the potential to lead to major economic and social benefits to Australia via royalty returns from drug sales and reduced costs for health care for patients with these diseases.
Bioengineering Endovascular Prostheses With Proactive Biocompatibility
Funder
National Health and Medical Research Council
Funding Amount
$627,950.00
Summary
Metallic cardiovascular implants, such as stents, used in the treatment of heart disease are not compatible with blood. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of metal alloys, and shown a significant improvement in their compatibility. Stents coated using our technology stand to dramatically improve the treatment of cardiovascular disease.
Bioengineering Synthetic Elastin Conduits For Arterial Revascularisation
Funder
National Health and Medical Research Council
Funding Amount
$624,776.00
Summary
An arterial substitute with both physical and biological properties that mimic those of the human vasculature has long been the holy grail of vascular tissue engineering. We propose synthetic elastin can form the basis of a durable, clinically effective small diameter vascular graft and fill a significant unmet need for a biocompatible vascular substitute.
Pre-clinical Validation Of A Novel Implant For Bone Tissue Engineering
Funder
National Health and Medical Research Council
Funding Amount
$435,767.00
Summary
The aim of this grant to was examine a new method for manufacturing implants to improve repair of critical bone defects. It involves new technology for the manufacture of porous scaffolds and testing their delivery in a biological, bone repair setting.